帕金森病与疲劳

目的探讨异质性帕金森病(Parkinson’s disease,PD)患者出现疲劳的临床特征及疲劳与运动及非运动症状的关联,明确症状的归属,以期寻找缓解症状的治疗方法。方法连续收集2014-04-2016-06就诊于广州市第一人民医院神经科运动障碍疾病门诊及住院的144例PD患者的病历资料,按帕金森病异质分组原则分组,全部患者采用疲劳严重程度(fatigue severity scale,FSS)和疲劳量表(fatigue scale,FS-14)评价疲劳,同时完成PD运动症状(motor symptoms,MS)、非运动症状(nomotor symptoms,NMS)、日常生活能力及质量相关的量表分析。结果 144例PD患者中,有疲劳症状60例(41.47%),疲劳组中早期PD且无其他NMS症状10例。异质性帕金森病不同组别比较显示强直为主型、女性及中晚期PD患者发生疲劳机会增加。单因素分析示,PD患者年龄、病程、H-Y分级、运动症状评分(UPDRS评分Ⅲ(R)、UPDRS评分Ⅲ总分)及UPDRSⅣ部分得分疲劳组得分均高于非疲劳组;非运动症状评分(NMSS)提示,疲劳组患者的NMS出现程度及频率均较非疲劳组严重,差异有统计学意义(P0.05);疲劳组精神情绪总体状况(UPDRSⅠ)、抑郁(HAMD)、焦虑(HAMA)、白天嗜睡(ESS)均明显高于非疲劳组;MMSE评分证实2组患者智能正常,差异无统计学意义(P0.05),但疲劳组较非疲劳组MMSE得分有下降趋势;疲劳组日常生活动能力(UPDRSⅡ)和生活质量PDQ39评分均显著高于非疲劳组,英格兰日常生活能力量表Schwab显著低于非疲劳组,差异均有统计学意义(P0.05)。多重线性回归分析,NMSS程度、焦虑、抑郁评分与疲劳显著相关。结论 PD患者疲劳的发生率高;异质性帕金森病发生疲劳几率不同;单因素分析疲劳组PD患者病程更长,运动症状及病情更严重,NMS更多、更重,生活质量更差;NMSS的程度、焦虑、抑郁是导致疲劳的主要原因;部分疲劳组患者的疲劳发生与MS及NMS无关,提示疲劳可能是PD病程中的独立的非运动症状之一。     

早期帕金森病非运动症状对患者生活质量的影响

目的探讨早期帕金森病(PD)患者非运动症状(NMS)的发病情况及其对患者生活质量的影响。方法选择我院门诊及住院160例早期PD患者为观察组;选取同期门诊就诊的非PD患者100例为对照组。采用帕金森病非运动症状筛查量表对2组的NMS发病情况进行调查;采用帕金森病生活质量问卷(PDQ-39)评估患者生活质量;分析PD患者的NMS的发病情况及其对帕金森病患者生活质量的影响。结果观察组NMS平均(8.1±4.2)分,显著高于对照组(4.9±3.1)分(P0.01);焦虑、抑郁、大便排空不完全感、注意力障碍、失眠、记忆力下降对日常生活有显著的负面影响(P0.05)。结论神经精神症状、自主神经功能障碍、睡眠障碍是PD患者最常见的非运动症状,对帕金森病患者生活质量有显著的负面影响,早期评估和干预非运动症状对提高患者生活质量有重要意义。     

帕金森病非运动症状在评价帕金森病严重程度中的作用

目的探讨帕金森病(PD)非运动症状(NMS)的发病情况及其在评估帕金森病严重程度中的作用。方法选择我院2010-10—2014-06门诊及住院210例PD患者为观察组;选取同期门诊就诊的非PD患者180例为对照组。采用帕金森病非运动症状筛查量表对2组的NMS发病情况进行调查,分析PD患者的NMS临床特征及其在评估帕金森病严重程度中的作用。结果观察组NMS发生总数为1~23项,平均(11.7±5.3)项,显著高于对照组(P0.01);各项NMS发生率比较,观察组显著高于对照组(P0.01)。分析显示,PD患者NMS发生项数与病程和病情严重程度具有相关性(P0.05)。结论自主神经功能障碍、睡眠障碍、焦虑、抑郁是PD患者最常见的非运动症状,NMS发生总数与PD患者病程及病情严重程度相关,可以作为评价PD严重程度和进展的一项指标。     

帕金森病非运动症状的临床特征及影响因素分析

目的探讨帕金森病(PD)非运动症状(NMS)的临床特征及其影响因素。方法选取2014年1月至2016年12月期间共126例PD患者作为研究对象,采用NMS量表对患者进行评估,筛选存在NMS的PD患者,对其NMS进行分析,并对NMS的PD患者与无NMS的PD患者的临床资料进行对比分析,对导致PD患者出现NMS的相关因素进行单因素、多因素Logistics回归分析。结果 126例PD患者中,出现至少一项NMS的患者共有77例(61.11%),主要包括认知功能障碍、精神障碍、睡眠障碍、感觉障碍、自主神经功能障碍。经单因素和多因素Logistics回归分析发现,导致PD患者出现NMS的相关因素主要为临床类型、病情分级、病程。结论 PD患者的非运动症状发生概率相对较高,主要表现为认知功能障碍、精神障碍、睡眠障碍、感觉障碍、自主神经功能障碍,其发生主要与临床类型、病情分级以及病程有关。     

早期初诊帕金森病患者非运动症状的研究

目的探讨早期帕金森病(PD)患者不同年龄分组、不同临床亚型非运动症状(NMS)的特点。方法收集门诊首次就诊且发病在1年内的早期PD患者96例和正常对照者102例,调查临床资料及相关量表并进行比较。结果 91例(93.83%)患者至少出现1项NMS,常见症状依次为近记忆力下降(70.83%,68例)、便秘(48.96%,47例)、注意力下降(47.92%,46例),比例均高于对照组(均P0.01)。年龄≤60岁较年龄60岁感焦虑害怕或恐慌的发生率明显升高(P0.01);强直型尿急的发生率明显高于震颤型(P0.01)。结论早期PD患者非运动症状复杂多样。不同年龄组及不同临床亚型NMS的表现也有所差异。     

帕金森病患者非运动症状的发生及对日常生活能力的影响

目的 研究帕金森病(PD)患者非运动症状(NMS)的发生情况,及其对PD患者日常生活能力(ADL)的影响.方法 对107例PD患者进行NMS问卷(NMS Quest)调查,分析NMS的分布状况及临床特征,并采用统一PD评定量表(UPDRS)、Hoehn-Yahr分期、左旋多巴等效剂量、ADL问卷、MMSE评分进行评估,采用多元逐步线性回归探讨NMS对ADL的影响.结果 97.2%(104/107)的PD患者伴发不同程度的NMS,其发生数平均(8±5)个,其中尿频、便秘、记忆力下降最常见,发生率均超过50%;UPDRS-Ⅲ评分(28.0±16.4)分,能解释ADL总分变化的48.1%(R~2=0.481,P=0.000),引入NMS分值后,ADL分值可被解释的部分增加到51.1%.结论 PD患者普遍伴发NMS,而影响患者的ADL.PD可能是由NMS和运动症状共同组成的多系统神经变性疾病.PD患者的NMS在临床上应引起同样的重视,运动症状与NMS同治,才能提高疗效和ADL.     

帕金森病患者非运动症状发生及相关影响因素的研究

目的 研究帕金森病(PD)非运动症状的发生和分布情况及其与多种相关因素的关系。方法 对68例原发性PD患者使用统一PD评分量表(uPDRs)、PD非运动症状30问卷量表(the PD NMS questionnaire,NMSQuest)、日常生活能力量表(ADL)和简易智能量表(MMsE)进行评分,并对非运动症状进行评估。结果 所有PD患者各个时期病程均有非运动症状的出现,平均每个PD患者出现9项左右不同的非运动症状,并且非运动症状的发生与PD疾病的进展相关,与Hoehn and yahr(H-Y)分级呈正相关(P<0.01),与UPDRsⅢ运动评分呈正相关(P<0.01),且影响患者的生活质量,与ADL评分呈负相关P<0.05),而与年龄、性别、PD发病类型和左旋多巴每日治疗量无关(P>0.05)。结论 非运动症状的发生在PD中很普遍,各项发生率随PD患者的临床特点及病程进展的情况变化,NMS发生数与PD的疾病严重程度呈正相关,对患者生活质量产生严重影响,需要全面认识和及时干预。     

帕金森病前驱期患者非运动症状研究

目的探讨帕金森病(PD)前驱期患者非运动症状特点。方法 2017年3月至2018年12月于南京市社区筛查共纳入36例PD前驱期患者(PD前驱期组)和36例年龄、性别及受教育年限相匹配的健康老年人(对照组)。所有受试者均采用统一帕金森病评定量表第三部分(UPDRS-Ⅲ)、简易智能评估量表(MMSE)、蒙特利尔认知评估量表(Mo CA)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和非运动症状问卷筛查量表(NMS Quest)进行评估。结果筛查到的PD前驱期患者占总筛查人数的3.02%。PD前驱期组UPDRS-Ⅲ评分、HAMD评分、HAMA评分和NMS Quest评分高于对照组,MMSE评分和Mo CA评分低于对照组,均差异有统计学意义(P0.05)。PD前驱期患者中100%至少出现一种非运动症状。PD前驱期组各非运动症状症候群发生率均高于对照组,差异有统计学意义(P0.05)。结论 PD前驱期患者非运动症状复杂多样,应重视社区中存在非运动症状人群并及时筛查。     

帕金森病非运动症状研究进展

帕金森病(PD)是好发于中老年的神经系统变性疾病,PD不仅表现出核心的运动症状(MS),还表现出各种的非运动症状(NMS),NMS是PD发生频率很高且非常重要的症状,可以出现在PD的任何阶段。NMS能促进PD的早期诊断,也是引起PD患者日常生活能力及生命质量降低的重要原因。文中从感觉障碍、神经精神障碍、自主神经功能障碍、睡眠障碍、疲劳等方面对PD患者的NMS相关研究进展进行综述。     

帕金森病患者便秘的研究进展

帕金森病(Parkinson disease,PD)是一种中老年常见的神经变性病,慢性致残率高。疾病早期除了典型运动症状,患者还诉嗅觉减退、睡眠障碍、抑郁和便秘等非运动症状(non-motor symptoms,NMS)。临床中随着抗帕金森药物的应用,NMS成为影响患者生活质量的主要因素[1],而便秘是临床常见、发生率很高的     

帕金森病初诊患者的非运动症状特点及其性别差异

目的 探讨初诊帕金森病(PD)患者非运动症状(NMS)的特点及其性别差异.方法 选取首次就诊的PD患者203例(男性102例,女性101例)及正常对照者255例(男性110例,女性145例),收集入组对象的临床资料并采用简易智能评估量表(MMSE)、蒙特利尔认知评估量表(MoCA)、汉密尔顿抑郁量表(HAMD)、汉密尔...     

Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?

BackgroundLow serum uric acid (UA) has been consistently shown to be associated with increased risk of Parkinson's disease (PD), and to predict faster motor and cognitive decline in established PD. The aim of the present study is to evaluate the relationship between serum UA and non-motor symptoms (NMS) in de novo PD.MethodsSerum UA was measured in consecutively recruited, early drug-naïve PD patients. Exclusion criteria were: treatment with UA modifying drugs; current smoking status; metabolic or cardiac morbidity. All patients completed the NMS Questionnaire (NMSQuest). The relationship between UA levels and NMSQuest domains was explored by logistic regression, subsequently adjusted for age, gender, disease duration (months since reported motor onset) UPDRS part III, H&Y scale, and MMSE. Regression analysis studied the overall relationship between UA levels and total NMS score, and was subsequently adjusted for age, gender, disease duration UPDRS part III, H&Y scale and MMSE.ResultsEighty PD patients were recruited. At logistic regression, higher UA levels were related to lower involvement of Attention/Memory (p = 0.004), Cardiovascular (0.009) and Sleep (p = 0.028) domains of NMSQuest. UA levels showed a significant negative correlation with total NMSQuest score at regression analysis (p = 0.001; Adjusted R-squared = 0.319).DiscussionThe present study investigated, for the first time, the relationship between NMSQuest and UA in de novo PD. Lower UA was related to higher NMSQuest total score and in particular to Attention/Memory, Cardiovascular and Sleep domains. Thus, UA seems to be a major candidate to be a valuable biomarker of such early features of PD as NMS.     

Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.

2006, there was, no single instrument (questionnaire or scale) for attempting a comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's disease (PD). The PD nonmotor group, a multidisciplinary group of experts including patient group representatives developed and validated the NMS screening questionnaire (NMSQuest) comprising 30 items. The NMSQuest is a self completed screening tool designed to draw attention to the presence of NMS. In this paper, we present the results gathered from 545 patients using the definitive version of the NMSQuest highlighting the prevalence of the wide range of NMS flagged in the NMSQuest from consecutive PD patients in an international setting.     

Quantitation of non-motor symptoms in Parkinson's disease

Background:  Disabling non-motor symptoms (NMS) associated with Parkinson's disease (PD), such as dementia and loss of balance, do not respond well to levodopa therapy and can lead to eventual death in patients with the disease. In 2006, a multidisciplinary group of experts and patient representatives developed an NMS screening questionnaire (NMSQuest) and a unified Non-Motor Symptoms Scale (NMSS) to address the need for simple identification and comprehensive assessment of NMS in patients with PD.
Methods and Results:  An international pilot study of 96 healthy controls and 123 patients with various stages of treated and untreated PD was conducted to demonstrate that the NMSQuest is a feasible, valid, and accepted tool.
Conclusion:  The majority of patients and caregivers felt that the questionnaire was clear and relevant to their daily lives. Data from 242 PD patients with no dementia were analysed in a pilot study on the clinimetric validation of NMSS. Similar to the NMSQuest study, the NMSS study revealed a significant correlation between progression of PD and increasing NMS burden. These studies suggest that the NMSQuest accurately detects the NMS, and that the NMSS closely correlates with quality of life for PD patients.     

International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.

Nonmotor symptoms (NMS) of Parkinson's disease (PD) are not well recognized in clinical practice, either in primary or in secondary care, and are frequently missed during routine consultations. There is no single instrument (questionnaire or scale) that enables a comprehensive assessment of the range of NMS in PD both for the identification of problems and for the measurement of outcome. Against this background, a multidisciplinary group of experts, including patient group representatives, has developed an NMS screening questionnaire comprising 30 items. This instrument does not provide an overall score of disability and is not a graded or rating instrument. Instead, it is a screening tool designed to draw attention to the presence of NMS and initiate further investigation. In this article, we present the results from an international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest). Data from 123 PD patients and 96 controls were analyzed. NMS were highly significantly more prevalent in PD compared to controls (PD NMS, median = 9.0, mean = 9.5 vs. control NMS, median = 5.5, mean = 4.0; Mann-Whitney, Kruskal-Wallis, and t test, P < 0.0001), with PD patients reporting at least 10 different NMS on average per patient. In PD, NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease. Furthermore, frequently, problems such as diplopia, dribbling, apathy, blues, taste and smell problems were never previously disclosed to the health professionals.     

The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire

The nonmotor symptoms (NMS) of Parkinson's disease (PD) are less well recognised and can be more troublesome to patients and carers than classical motor features. NMS are frequently missed during routine consultations and such under‐recognition may have implications on quality of care given that many NMS are treatable. To determine the proportion of patients not declaring NMS to healthcare professional (HCP) as assessed by self completion of the NMS questionnaire (NMSQuest), a validated, self‐completing questionnaire with 30 items. Multicentre international study. The data was collected from PD patients across all age groups and stages attending outpatient clinics in specialist and care of the elderly settings. 242 patients recruited and undeclared NMS ranged from 31.8% (diplopia) to 65.2% (delusions). The most frequently nondeclared symptoms were delusions, daytime sleepiness, intense and vivid dreams, and dizziness. In many, appropriate treatments for undeclared NMS were started only after these were recognised following completion of NMSQuest. NMS of PD are frequently undeclared at routine hospital consultation and may be related to the fact that patients often do not link these symptoms with PD or may be too embarrassed to discuss these. Use of NMSQuest allows patients to flag symptoms which may be otherwise undeclared and remain untreated when potential treatments exist. © 2010 Movement Disorder Society     

Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study

Nonmotor symptoms (NMS) are increasingly recognized as a significant cause of morbidity in later stages of Parkinson's disease (PD). Prodromal NMS are also a well recognized component of the clinical picture in some patients but the prevalence of NMS as presenting complaints, and their impact on clinical management, in pathologically‐proven cases of PD is unknown. The presenting complaints of 433 cases of pathologically‐proven PD archived at the Queen Square Brain Bank for Neurological Diseases were identified from the clinical case notes. 91/433 (21%) of patients with PD presented with NMS of which the most frequent were pain (15%), urinary dysfunction (3.9%), anxiety, or depression (2.5%). Presenting with NMS is associated with a delayed diagnosis of PD (Mann‐Whitney U, P = 0.001). These patients were more likely to be misdiagnosed initially and were more likely to have been referred to orthopedeic surgeons or rheumatologists than neurologists (nonmotor group 5.5% vs. motor group 44.2%, χ² P < 0.0001). NMS are commonly seen as presenting complaints in pathologically confirmed PD, and initial misdiagnosis may be associated with potentially inappropriate medical interventions. Presenting with NMS does not affect the motor response to medication, but is associated with shorter disease duration (χ² P = 0.016). © 2007 Movement Disorder Society     

Non-motor symptoms in Chinese Parkinson’s disease patients

This study was designed to survey the prevalence and distribution of non-motor symptoms (NMS) in Parkinson’s disease (PD) patients in Shanghai, China, and to investigate the association between NMS and health-related quality of life (HRQoL). One hundred fifty-five PD patients were evaluated using the NMS Questionnaire 30 (NMSQuest), Unified Parkinson’s Disease Rating Scale (UPDRS) and Parkinson’s Disease Questionnaire-39 (PDQ-39). These data were compared with an international cross-sectional study, and the associations of motor and non-motor measures with HRQoL were estimated. Predictors of HRQoL were sought through multiple linear regression analyses. Each PD patient had eight different individual NMS on average. The problems of memory (65.82%), constipation (64.56%) and nocturia (61.39%) were the most frequent complaints. NMS prevalence in PD patients in Shanghai was consistent with that in the international study, although the composition proportions were different. There was a significant association of PDQ-39 score with NMSQuest score (rs = 0.433, p = 0.000), UPDRS III score (rs = 0.473, p = 0.000), Hoehn and Yahr (H-Y) stage (rs = 0.567, p = 0.000), disease duration (rs = 0.220, p = 0.005), and levodopa equivalent dosage (rs = 0.263, p = 0.001). H-Y stage (disease severity) and NMS score were the strongest predictors for PDQ-39 score. This study confirmed that NMS are common in PD, occurring across all disease stages and have a great impact on quality of life. NMS progression contributes significantly to HRQoL decline, and should be well recognized and treated.